💼 05/25: Initiating Coverage on 10 New Names
With 91.3% in the Green, Time to Scout the Next Winners
Welcome back dear fellow 🧙♂️ Hermits 👋
Want more context? Track the journey so far:
💼 The Hermit Portfolio: April Update
💼 The Hermit Portfolio: May (previous) Interim Update
Index
Briefing
This twelfth update arrives with little fanfare, but those who read carefully will find more than they expected.
First, four portfolio holdings delivered extraordinary performance during the month of May, each in their own quiet way. Nebius surged +73%, BluMetric nearly doubled, Shelly and QXO climbed with strength. We’ve unpacked the core theses behind each of these moves in prior updates, and this month, they are unfolding as expected.
Second, in an age addicted to motion, this was a conscious act of restraint. We kept to our promises from the quarterly review and revisited the discipline behind inaction, exploring why it might have been our most impactful decision this quarter.
Third, we share the trades we would pursue and their reasoning:
Accumulating […] near $6.00, a mispriced asset still shrouded in oil-linked misunderstanding
Building a position in […] a company whose near-term catalyst may change everything between June and September
Fourth, we turn outward. This month delivered macro tremors too loud to ignore:
The U.S. sovereign credit rating was unanimously downgraded for the first time in decades
Brent crude slipped beneath $70, a price that destabilizes entire fiscal regimes
U.S. Treasuries are quietly repricing risk, suggesting that behind the market’s surface lies something far more uncertain
We explore how these undercurrents shape investor psychology and portfolio construction going forward.
Fifth, we’ll look at developments from 10 companies we find particularly compelling, including five fresh names we’ve never covered before. For each, we’ll include a brief explanation of why it caught our attention and how it earned a spot on our top candidates watchlist. These include…
Clinica Baviera, quietly expanding across DACH with no dilution and insider alignment
Dalata Hotels, trading below NAV, with conservative leverage and strong RevPAR
Myomo, a life-changing medtech name riding a reimbursement flywheel
…and others, each offering a different kind of asymmetric potential
🧙♂️ Finally, a quiet drumbeat in the background as we transition into our new structure, you’ll see the same principles, same voice… but behind it, a sharper and more deliberate engine.
Stage 3 is coming… And it will feel different, but the same.
Please note that this portfolio faithfully reflects the author’s personal seven-figure investment portfolio, which will be phased out as positions get established through the regulated Equity Focus FIL.
This publication is confidential and intended solely for the use of the person or entity to whom it is given or sent. It may not be reproduced, distributed, or transmitted without the author's prior written consent. By accepting to receive the full post as a 🧙♂️ Hermit Premium member, the recipient agrees to be bound by the foregoing limitations.
None of the following should be construed as investment advice. Please consult a financial advisor before making any investment decision. You will find a full disclaimer at the end of this post.
